AstraZeneca PLC

AZNCF

Get informed when a big investor buys or sells

Market Cap$294.4B

Close$

Compare to Similar Companies

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
AstraZeneca PLC	26	1.78%	21%	5.1	0.6

Earnings Call Q1 2026

April 29, 2026 - AI Summary

Q1 financial momentum was strong (and guidance reiterated): Total revenue +8% YoY (core product revenue +8%, alliance revenue +26%). Core gross margin 83%. Core operating profit +12% and core EPS +5% to $2.58 (growth held back by a low tax rate in Q1 2025). Full-year guidance reiterated: total revenue expected mid- to high single-digit growth; core EPS low double-digit growth at CER. FX expected low single-digit positive on revenue and neutral on core EPS.

Investing for launch/R&D pipeline while maintaining profitability: Core R&D +8% (active clinical trials +10%; patients enrolled +30% YoY). Core R&D remains ~23% of revenue in Q1; full-year expected at the upper end of low 20s %. SG&A +7%, partly due to prelaunch investments behind baxdrostat (U.S. PDUFA in Q2 2026) and upcoming launches (e.g., camizestrant, tozorakimab). Company expects CapEx to increase ~1/3 in 2026.

Commercial performance: growth offset by CVRM loss of exclusivity: Oncology/Rare Disease showed strong double-digit growth, and the U.S. grew double-digit (Europe high single digits / “high single digits” phrasing). Emerging markets ex-China +9%. China +2% YoY, with VBP impacting Farxiga/Lynparza/roxadustat; management is confident given positive 2026 NRDL outcomes. Biopharma overall -2% to $5.8bn, reflecting CVRM -6% (loss of exclusivity headwinds) and brand headwinds from Brilinta/Farxiga/roxadustat.

Exclusive for Stockcircle Pro members

$423.09

Current Fair Value

122.8% upside

Undervalued by 122.8% based on the discounted cash flow analysis.

Share Statistics

Market cap	$294.40 Billion
Enterprise Value	$319.39 Billion
Dividend Yield	$3.14 (1.78%)
Earnings per Share	$6.6
Beta	0.19
Outstanding Shares	1,551,000,000

Return

Return on Equity	21.16%
Return on Assets	9.03%
Return on Invested Capital	16.80%

Valuation & Multiples

P/E Ratio	25.98
PEG	47.18
Price to Sales	5.13
Price to Book Ratio	6.13
Enterprise Value to Revenue	5.44
Enterprise Value to EBIT	22.78
Enterprise Value to Net Income	31
Total Debt to Enterprise	0.1
Debt to Equity	0.63

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date

April 29, 2026

EPS Estimate

Average shareholder expectation

Revenue Estimate

$15.44 B

Average shareholder expectation

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

ESG Score

No data

About AstraZeneca Plc

CEO: Pascal Soriot

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...

Relevant Senate Committees

Finance

Most powerful committee for pharma; oversees Medicare and Medicaid. It dictates drug pricing negotiations, rebate policies, and international tax laws that affect corporate earnings.

Appropriations

Determines the actual funding levels for the FDA and NIH, influencing the speed of drug approvals and the amount of federal funding available for collaborative biomedical research.

Health, Education, Labor, and Pensions

Directly oversees the FDA and NIH; this committee's legislation determines the regulatory hurdles for drug approval and clinical trials, which is fundamental to AstraZeneca's pipeline.

Judiciary

Controls intellectual property and patent law; AstraZeneca's valuation is heavily dependent on patent protections and the prevention of generic competition managed through this committee's jurisdiction.

Special Committee on Aging

Investigates drug pricing, Medicare, and conditions like cancer and cardiovascular health, which are core therapeutic areas for AstraZeneca; its hearings create significant headline and reputational risk.

Veterans' Affairs

The Department of Veterans Affairs is one of the largest purchasers of drugs in the world; committee decisions regarding VA formularies and drug pricing directly impact AstraZeneca's US revenue.